Author: admin

Unmanned Underwater Vehicles Market worth $11.1 Billion by 2030, at a CAGR of 15.0%

“Unmanned Underwater Vehicles Market”
The Unmanned Underwater Vehicles Market Value is projected to be USD 11.1 billion by 2030, growing from USD 4.8 billion in 2024, at a Compound Annual Growth Rate (CAGR) of 15.0% during the forecast period.

The report “Unmanned Underwater Vehicles Market by Type (Autonomous Underwater Vehicles (AUVs), Remotely Operated Vehicles (ROVs)), Product Type), Propulsion, Application, System, Speed, Shape, Depth and Region – Global Forecast to 2030” The market is valued at USD 4.8 billion in 2024 and is projected to reach USD 11.1 billion by 2030, at a CAGR of 15.0% from 2024 to 2030. The Unmanned Underwater Vehicles market is driven by the increasing technological advancement, increasing naval spending and increasing demand for UUVs for various commercial and defense applications. The increasing need of UUVs for oceanographic research, offshore oil and gas exploration, underwater infrastructure inspection, and maritime security is driving the market growth.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=140710720

Browse 473 market data Tables and 117 Figures spread through 417 Pages and in-depth TOC on “Unmanned Underwater Vehicles Market”

View detailed Table of Content here – https://www.marketsandmarkets.com/Market-Reports/unmanned-underwater-vehicles-market-140710720.html

Based on the ROV- system, the Propulsion systems segment is estimated to hold the highest market share during the forecast period.

Based on the ROV- systems, the propulsion systems segment is estimated to lead the Unmanned Underwater Vehicles Industry from 2024 to 2030. The propulsion systems segment is growing rapidly due to technological advancement in energy density of power sources, efficiency improvements in thruster design, and the integration of advanced control algorithms for precision maneuvering. Enhanced battery technologies, such as lithium-ion with higher energy densities, enable longer mission durations and increased operational range are driving the market growth of propulsion systems segment by ROV- systems.

Based on the AUV- system, the Payloads segment is estimated to hold the highest market share during the forecast period.

Based on the AUV- system, the Payloads segment is estimated to hold the highest market share during the forecast period. The growth of the segment is due to the advancements in sensor miniaturization, enhanced data processing capabilities, and the integration of multi-sensor fusion technologies. Innovations in high-resolution imaging sonars, and chemical sensors enables comprehensive environmental monitoring, resource exploration, and surveillance activities. The adoption of lightweight, energy-efficient components has increased the operational durations and payload capacities.

Based on regions, the Asia Pacific accounts for largest market share in Unmanned Underwater Vehicles market.

Based on region the Asia Pacific market is estimated to accounts for largest market share during the forecast period. There is increasing demand for the deployment of AUVs and ROVs for underwater exploration and surveillance for scientific research, defense and security applications, and offshore oil and gas exploration activities in the region. The rise in governmental and institutional investments in marine research and the development of maritime infrastructure are fueling the market growth in Asia Pacific region.

Key Players

The Unmanned Underwater Vehicles Companies is dominated by a few globally established players such as Kongsberg (Norway), Saab AB (Sweden), Boeing (US), Oceaneering International, Inc. (US) and Fugro (Netherlands).

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

In addition, MarketsandMarkets SalesIQ enables sales teams to identify high-priority accounts and uncover hidden opportunities, helping them build more pipeline and win more deals with precision.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Delray Beach
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/unmanned-underwater-vehicles-market-140710720.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Unmanned Underwater Vehicles Market worth $11.1 Billion by 2030, at a CAGR of 15.0%

Compact Construction Equipment Market Size & Forecast Report 2032

“Compact Construction Equipment Market”
Compact Construction Equipment Market by Type (Excavator, Loader, Skid Steer, Track Loader, Compactor, Telehandler), Propulsion, Power Output, Engine Capacity, Function, Electric Construction Equipment, Battery Chemistry, & Region – Global Forecast to 2032

The Compact Construction Equipment market size is projected to grow from USD 39.52 billion in 2025 to USD 56.05 billion by 2032, at a CAGR of 5.1%.

The compact construction equipment industry is expanding in North America due to increased regional residential and infrastructure spending, population expansion, and rising disposable income. Technological advancements in compact construction equipment, such as automation and telematics integration, will increase productivity, increasing the demand for new and advanced compact construction equipment.

“Mini Excavators will account for the largest share of compact construction equipment in 2025.”

Mini excavators are estimated to have the largest market share in the global compact construction equipment market in terms of value. Asia has a strong demand for mini excavators due the equipment’s ability to operate in diverse terrains and handle heavy loads, making them ideal for excavation, grading, and demolition tasks. Almost all construction equipment manufacturers offer mini excavators, and all manufacturers offer a variety of models in the product portfolios for this equipment. Kubota Corporation (Japan), Kobelco (Japan), and Caterpillar (US) lead the global market for Mini Excavators. Mini excavators offered by these companies fall in HP ranges from 20 HP to 70 HP. These lower power output equipment’s have major applications in residential sector. Mini excavators falling under this category have benefits such as low operating costs, better fuel efficiency, improved maneuverability and they are easy to control. Mini Excavators are also leading the shift to electrification. The majority of the OEMs developing electric-propelled equipment offer electric excavators. Industry experts say

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=89115103

“61-100 HP power output compact construction equipment to register the fastest growth during the forecast period.”

61-100 HP power output equipment is estimated to experience the fastest growth rate in the compact construction equipment market by power output. Skid Steers, backhoe loaders, and compact track loaders will dominate the market in this segment. This power output range is preferred in construction equipment because it can meet high torque and power demands. The demand for this range of equipment is particularly strong in Asian countries, driven by large-scale infrastructural development projects like roads, commercial complexes, and smart city projects. The major players in this category include JCB (UK), CNH Industrial (UK), Caterpillar (US), and Deere & Company (US). Recent developments in this segment include Kubota Corporation launching the SVL97-4 Compact Track loader in January 2025 and Deere & Company launching the 335 P-tier compact track loader in June 2024.

North America is estimated to be the largest compact construction equipment market.

North America is expected to be the largest market for compact construction equipment in the coming years. The rise in residential construction spending drives the growth of the compact construction equipment market in the region. The US is the major market in North America for compact construction equipment. As the population grows, there is a higher demand for new housing, boosting the need for construction equipment. In December 2024, the US approved 1.48 million building permits and completed 1.54 million housing units, with residential construction increasing by 2.6% from December 2023. The return of the Trump administration in the United States can have several significant impacts on the construction equipment market in the region. One of the key promises of Trump’s previous administration was a major push for infrastructure development, including roads construction, reconstruction of bridges and airports. The previous trump government also focused on imposing lower taxes on businesses and a more pro-business environment, which could lead to increased investments in both public and private infrastructure, creating demand for construction equipment. The negative factors from the new government maybe, Trump’s previous administration-imposed tariffs on a variety of products, including steel and aluminium, a similar return to these types of trade policies is expected, which will increase the costs of raw materials used in construction equipment manufacturing, such as steel and copper.

The Canadian construction equipment market is also expected to grow during the forecast period. In Canada, building construction investment grew by 2.8% to USD 21.4 billion in June 2024, and year-on-year investments rose by 10%. Mexico’s construction output also grew by 12.57% in June 2023 compared to the previous year. Hence, with the growing investments in the residential sector and the presence of major manufacturers like Caterpillar and Deere & Company in the region, the demand for compact construction equipment is estimated to be the highest.

Request Free Sample Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=89115103

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/compact-construction-equipment-market-89115103.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Compact Construction Equipment Market Size & Forecast Report 2032

Diabetic Retinopathy Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Diabetic Retinopathy Pipeline Insight” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Diabetic Retinopathy pipeline landscape. It covers the Diabetic Retinopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Retinopathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Diabetic Retinopathy Treatment Landscape. Click here to read more @ Diabetic Retinopathy Pipeline Outlook

Key Takeaways from the Diabetic Retinopathy Pipeline Report

  • In March 2025:- Vantage Biosciences Ltd announced a study to evaluate the Efficacy and Safety of Orally Administered VX-01 in Diabetic Retinopathy of Non-Proliferative Type (NPDR).
  • In March 2025:- Invirsa Inc. announced a phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during a 12-week dosing period in subjects with non-center involved DME (NCIDME) associated with NPDR [Part 1] and during an 8-week dosing period in subjects with center-involved DME (CIDME) associated with NPDR [Part 1].
  • In March 2025:- Incepta Pharmaceuticals Ltd conducted a study to to Compare Efficacy & Safety Between Ranibizumab 10mg/ml Injection of Incepta and Lucentis in Patients With Diabetic Macular Edema by ITV Injection.
  • In March 2025:- EyePoint Pharmaceuticals Inc. announced a study of Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Diabetic Macular Edema (DME).
  • DelveInsight’s Diabetic Retinopathy pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Diabetic Retinopathy treatment.
  • The leading Diabetic Retinopathy Companies such as Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others.
  • Promising Diabetic Retinopathy Pipeline Therapies such as Runcaciguat (BAY1101042), OTT166, COLIRIOBCN070660, Brimonidine, and others.

Discover groundbreaking developments in Diabetic Retinopathy therapies! Gain in-depth knowledge of key Diabetic Retinopathy clinical trials, emerging drugs, and market opportunities @ Diabetic Retinopathy Clinical Trials Assessment

Diabetic Retinopathy Emerging Drugs Profile

  • Tarcocimab tedromer: Kodiak Sciences

Tarcocimab is an investigational anti-VEGF therapy built on Kodiak’s proprietary Antibody Biopolymer Conjugate (“”ABC””) Platform and is designed to maintain potent and effective drug levels in ocular tissues for longer than existing available agents. Kodiak’s objective with tarcocimab is to enable earlier treatment and prevention of vision loss for patients with diabetic retinopathy and to develop a new durability agent to improve outcomes for patients with retinal vascular diseases. Currently, the drug is in Phase III stage of its clinical trial for the treatment of diabetic retinopathy.

  • OTT166: Ocuterra Therapeutics

Nesvategrast (OTT166) is an investigational, novel, patented, potent and selective small molecule RGD integrin inhibitor designed with purpose engineering to have an optimum balance of physiochemical properties to allow it to distribute to the retina in high concentrations after topical (eye drop) administration to the eye. In preclinical studies, nesvategrast selectively inhibited key RGD integrin subtypes, including αvβ3, to regulate cellular responses to VEGF and other growth factors known to contribute to development and progression of diabetic retinopathy and other ocular diseases. In early clinical trials in patients with diabetic retinal disease, nesvategrast eye drops have demonstrated preliminary evidence of tolerability and biological activity. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diabetic retinopathy. 

  • APX3330: Apexian Pharmaceuticals

APX3330 is a first-in-class, small molecule, oral inhibitor of the transcription factor regulator Ref-1 (reduction-oxidation effector factor-1). With a novel dual mechanism of action, APX3330 blocks the downstream pathways those involving angiogenesis (VEGF) and inflammation (NFkB) to decrease abnormal activation of both angiogenesis, and of inflammatory pathways that are implicated across several ocular diseases, including DR, DME, and age-related macular degeneration (AMD). APX3330 has shown a favorable safety and tolerability profile in 12 clinical trials conducted in healthy, hepatitis, cancer, and diabetic subjects. Currently, the drug is in Phase II stage of its clinical trial for the treatment of diabetic retinopathy.

OTX-TKI: Ocular Therapeutix

OTX-TKI is an investigational bioresorbable, hydrogel implant incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic properties, being evaluated for the treatment of wet age-related macular degeneration (wet AMD) and other retinal diseases. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diabetic retinopathy.

The Diabetic Retinopathy Pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Retinopathy with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Retinopathy Treatment.
  • Diabetic Retinopathy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Diabetic Retinopathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Retinopathy market

Stay informed about the Diabetic Retinopathy pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Diabetic Retinopathy Unmet Needs

Diabetic Retinopathy Companies

Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others.

Diabetic Retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Diabetic Retinopathy Pipeline Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Transform your understanding of the Diabetic Retinopathy Pipeline! See the latest progress in drug development and clinical research @ Diabetic Retinopathy Market Drivers and Barriers, and Future Perspectives

Scope of the Diabetic Retinopathy Pipeline Report

  • Coverage- Global
  • Diabetic Retinopathy Companies- Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others.
  • Diabetic Retinopathy Pipeline Therapies- Runcaciguat (BAY1101042), OTT166, COLIRIOBCN070660, Brimonidine, and others.
  • Diabetic Retinopathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Diabetic Retinopathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Dive deep into rich insights for new drugs for Diabetic Retinopathy Treatment, Visit @ Diabetic Retinopathy Market Drivers and Barriers, and Future Perspective

Table of Content

  1. Introduction
  2. Executive Summary
  3. Diabetic Retinopathy: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Diabetic Retinopathy– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. KSI-301: Kodiak Sciences
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. RGX 314: Regenxbio Inc
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. OTX-TKI: Ocular Therapeutix
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Diabetic Retinopathy Key Companies
  21. Diabetic Retinopathy Key Products
  22. Diabetic Retinopathy- Unmet Needs
  23. Diabetic Retinopathy- Market Drivers and Barriers
  24. Diabetic Retinopathy- Future Perspectives and Conclusion
  25. Diabetic Retinopathy Analyst Views
  26. Diabetic Retinopathy Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/diabetic-retinopathy-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diabetic Retinopathy Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Ashley Paul Shines Bright with New Pop Dance Single “Golden Tickets”

Dynamic Track Brings Together Top Talent for an Electrifying Sound

Pop sensation Ashley Paul is turning up the heat with her latest single, Golden Tickets — a vibrant dance anthem that’s destined to ignite dance floors worldwide. Known for her powerhouse vocals and magnetic energy, Ashley’s newest release is a high-octane storytelling anthem designed to captivate and inspire.

Golden Tickets was crafted by an exceptional team of industry talent. The track was co-written by Taylor Helgeson, best known for his work on Aaron Carter’s album “Love”, with production led by Dielog and Emma Oliver. Their combined expertise has resulted in an energetic, feel-good sound that blends pulsating beats with infectious melodies — the perfect recipe for dance music lovers.

With its upbeat tempo, empowering lyrics, and a mysterious, sultry intro, Golden Tickets encourages listeners to embrace life’s opportunities and chase their dreams fearlessly. As Ashley puts it, “Test your limits” — and so she does. The track’s dynamic production, coupled with Ashley Paul’s signature vocal style, creates an electrifying experience that’s sure to become a club favorite.

“I wanted Golden Tickets to be a celebration — something that makes people feel excited about seizing the moment and stepping into their best life,” said Ashley Paul. “2025 is the year we spin gold, turn our world around, and create something extraordinary. I’m incredibly grateful to the amazing writers and producers who helped bring this vision to life.”

Golden Tickets is now available on all major streaming platforms. Fans can also look forward to a visually stunning music video set to premiere soon, adding yet another layer of excitement to this highly anticipated release.

Exciting news for fans: Special remixes of Golden Tickets are set to drop in April, promising fresh new takes on this energetic hit.

Follow Ashley Paul’s journey and stay updated on upcoming performances and releases:

Instagram: @official_ashley_paul

Official Website: www.ashpaulmusic.com

Media Contact
Company Name: ICT PR
Contact Person: H Davidson
Email: Send Email
Phone: 323 513 4804
City: Los Angeles
State: CA
Country: United States
Website: www.iconnectyou.today

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ashley Paul Shines Bright with New Pop Dance Single “Golden Tickets”

CE-LINK Intelligent BMS System Offers Eight Protection Mechanisms to Guard Battery Safety

With the growing demand for reliable and efficient portable power solutions, portable power stations have become indispensable for outdoor sports enthusiasts, emergency backup power, and off-grid living. Ensuring the safety and longevity of batteries is a top priority for users. CE-LINK’s well-designed, intelligent Battery Management System (BMS) plays an important role in maintaining the health and performance of portable power stations, preventing potential hazards, and optimizing energy efficiency.

What is an Intelligent BMS?

An intelligent BMS is an advanced control system that monitors, manages, and protects the batteries in a portable power station. It oversees key parameters such as voltage, current, temperature, and state of charge (SoC) to optimize battery performance continuously. Unlike traditional BMS, intelligent BMS combines intelligent data analysis technology to realize condition monitoring and real-time data analysis functions.

The main role of intelligent BMS is to ensure safety and efficiency. Lithium-ion batteries commonly used in portable power stations are prone to risks such as overcharging, overheating, and short circuits. The intelligent BMS reduces these risks by dynamically adjusting the charge rate, balancing the batteries, and shutting down the system in the event of an anomaly. It also extends battery life by preventing deep discharges and optimizing charge cycles.

Eight protection mechanisms

  • Undervoltage Protection

When the battery voltage drops too low, the BMS alerts automatically cut off the power supply to prevent over-discharging the battery, leading to capacity loss and irreversible damage.

  • Over Voltage Protection

To prevent overcharging from swelling the battery, when the battery reaches its maximum safe voltage threshold, the system will stop charging to avoid potential damage to internal components.

  • Overcurrent Protection

During charging and discharging, the current can spike quickly. If the BMS detects excessive current, it will either limit the output or interrupt the circuit to ensure user safety.

  • Overload Protection

The system automatically detects and limits the amount of excessive power consumed by connected devices to prevent sudden shutdowns and damage to connected devices. This is especially important when powering multiple high-power devices.

  • Over Temperature Protection

High temperatures reduce battery performance, accelerate battery degradation life, and pose a safety risk. When the BMS monitors that the battery temperature exceeds the safety threshold, the system will initiate cooling measures or shut down the power station.

  • Low-Temperature Protection

Extreme cold conditions can lead to a decrease in battery charging efficiency. The BMS keeps the battery healthy by restricting the portable power station from charging in freezing temperatures.

  • Short Circuit Protection

When a short circuit is detected, the system immediately cuts off power to prevent sparks, fire, and permanent battery damage. This is an important safety feature for indoor and outdoor use.

  • SOH (State of Health) Monitoring Protection

The BMS continuously monitors the health of the battery. Battery performance, efficiency, and longevity are improved by tracking battery data, training learning battery algorithms, and continuously updating battery model characterization data. This allows users to optimize usage and perform maintenance or replacements when needed.

The intelligent BMS system offers eight protection functions that ensure comprehensive battery safety and performance. If the system detects abnormal conditions, it automatically adjusts the output of each component and cuts off the power supply when necessary to prevent damage.

How does the Intelligent BMS work?

Intelligent BMS combines hardware and software to achieve its goal of managing battery health and performance.

  • Sensors: Measure voltage, current, and temperature in real time.

  • Microcontrollers: Process sensor data and execute control algorithms.

  • Intelligent algorithms: Analyze historical data to predict battery behavior and optimize performance.

  • Communication Interface: Allows the user to monitor battery status through an application or display.

  • Protection Mechanisms: Regulate the overall energy of the battery and automatically disconnect the battery in the event of a failure.

“Intelligent BMS is the key to the innovation behind modern energy solutions that ensure portable power stations are safe, efficient, and durable.” Mr. Huang, CE-LINK Product Manager, said. “Whether users are camping in the wilderness or preparing for a power outage, the intelligent BMS keeps portable power stations ready to supply power.”

About CE-LINK

Founded in 2004, CE-LINK is a leader in portable power solutions, specializing in innovative and high-quality energy products. Known for its commitment to safety, reliability, and sustainability, CE-LINK continues to push boundaries, delivering solutions that meet the evolving power needs of modern users.

For more information on CE-LINK and its products, visit:

Website: www.ce-link.com

LinkedIn: www.linkedin.com/company/ce-link

Facebook: www.facebook.com/CELINK.ELECTRONICS

YouTube: www.youtube.com/@ce-linkelectronics3909

Media Contact
Company Name: CE LINK LIMITED
Email: Send Email
City: Dongguan
State: Guangdong
Country: China
Website: www.ce-link.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: CE-LINK Intelligent BMS System Offers Eight Protection Mechanisms to Guard Battery Safety

Pharmaceutical Packaging Market – Size, Segmental analysis, Regional Overview, Company Market share, Forecast, 2025 – 2028

“The pharmaceutical packaging market is evolving with innovations in sustainable materials, smart packaging, and stringent regulations. Rising demand for biologics and personalized medicine further drives growth. Ensuring safety, compliance, and efficiency will be key to shaping the market’s future expansion.”
The pharmaceutical packaging market is evolving with innovations in sustainable materials, smart packaging, and stringent regulations. Rising demand for biologics and personalized medicine further drives growth. Ensuring safety, compliance, and efficiency will be key to shaping the market’s future expansion.

The global pharmaceutical packaging market size is estimated to be USD 132.0 billion in 2023 and is projected to reach USD 269.9 billion at a CAGR of 15.4% during the forecast period. The reports 2025 research report offers an analytical view of the industry by studying different factors like pharmaceutical packaging market growth, consumption volume, Market Size, Revenue, Market Share, Market Trends, and pharmaceutical packaging industry cost structures during the forecast period from 2025 to 2028. The surge in urbanization, evolving lifestyles, increased disposable income, a growing preference for sustainable packaging, and global awareness of diseases are driving the expansion of the pharmaceutical packaging market. However, challenges include the elevated costs of raw materials used in manufacturing packaging products. Financial constraints, lack of information, outdated equipment, lack of proper staff, and awareness of proper healthcare practices are the major challenges that limit access to healthcare services. Opportunities arise from the rising demand for sustainable packaging, as it reduces waste and minimizes the impact of pharmaceutical products on the environment.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=890

“Plastic bottles is largest growing segment on the basis of type, in terms of value, during the forecast period.”

The demand for plastic bottles in the pharmaceutical packaging market is due to several factors including improved barrier properties, low water absorption, high impact strength, transparency, high dimensional stability, resistance to strain, heat, and flame resistance. Plastic bottles offer pharmaceutical companies convenience in transportation due to their ease of handling and reduced risk of breakage compared to glass bottles. Their durability minimizes the potential for product loss and safety concerns associated with breakages, making them a preferred choice in the pharmaceutical plastic bottle market. The use of plastic bottles aligns with stringent government regulations, underscoring their suitability for pharmaceutical packaging.

“Primary packaging form is largest growing segment on the basis of packaging type, in terms of value, during the forecast period.”

Various factors contribute to the increasing demand for the primary packaging segment in the pharmaceutical packaging market. These include the increasing prevalence of diseases, advancements in biotechnology and novel therapies, innovations in materials, rising healthcare expenditures, diversification of product portfolios, adherence to regulatory standards and quality assurance, as well as consumer preferences. The protection of pharmaceutical products from external factors such as light, air, moisture, and contaminants is essential for maintaining their stability and efficacy, making primary packaging a critical component.

“Plastic is largest growing segment on the basis of raw material, in terms of value, during the forecast period.”

The increasing prominence of plastic raw materials in the pharmaceutical packaging market can be attributed to several factors. Firstly, plastics provide a versatile platform for designing and implementing a diverse range of packaging solutions tailored to meet specific pharmaceutical requirements. Additionally, the cost-effectiveness of plastics, both in production and transportation, contributes to overall economic efficiency. The lightweight characteristics of plastic materials facilitate easier handling, resulting in reduced transportation costs and minimized environmental impact. Moreover, plastics boast excellent barrier properties, offering effective protection for pharmaceutical products against external factors such as moisture and contaminants.

Get a Sample Copy of This Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=890

“Oral drug delivery is largest growing segment on the basis of drug delivery, in terms of value, during the forecast period.”

Several factors contribute to the dominance of oral drug delivery in the pharmaceutical packaging market. Firstly, a significant portion of pharmaceutical preparations is intended for oral consumption, making oral drug delivery packaging the largest segment in the market. Secondly, oral drug delivery packaging is cost-effective, offering a practical and economical choice for pharmaceutical companies. Thirdly, the flexibility in designing dosage forms makes oral drug delivery an ideal option for pharmaceutical companies. Lastly, the increasing prevalence of chronic diseases and the growing global demand for pharmaceutical products have fueled the expansion of the oral drug delivery packaging market.

“North America is largest growing segment on the basis of region, in terms of value, during the forecast period.”

North America has the largest market share in the pharmaceutical packaging market in terms of value.

Europe has the second largest market share in the pharmaceutical packaging market in terms of value. With prominent consumers like the US, Canada, and Mexico leading the trend, the region thrives on increased construction activities and is a hub of major packaging manufacturers. The pharmaceutical packaging market in North America is experiencing growth due to rapidly evolving pharmaceutical therapies, new drug innovations, and the increasing demand for smart packaging. In North America, essential market drivers include a heightened demand for diverse drug delivery methods, the integration of additional features in packaging products, and the development of packaging solutions with child-resistant and senior-friendly features.

Pharmaceutical Packaging Companies

Berry Global Group, Inc. (US), Gerresheimer AG (Germany), Amcor Plc (Switzerland), Schott AG (Germany), and AptarGroup, Inc. (US) are some of the established players in the pharmaceutical packaging market. The growing trend of rising consumer awareness for safe and secure packaging solutions is driving the market. These players have adopted various strategies such as mergers & acquisitions, joint ventures, and expansion to strengthen their market position.

Berry Global Group, Inc. is a leader in plastic packaging. It operates through three business segments, namely, engineered materials; health, hygiene & specialties; and consumer packaging. Pharmaceutical devices and packaging are offered under the consumer packaging segment. The company provides non-woven film and lamination for a wide range of medical & pharmaceutical applications and for healthcare packaging needs. It offers storage plastic components such as containers, food service products, closures and over caps, and bottle & prescription containers and tubes. The company serves various industries, such as food, healthcare, shipping & transportation, building & construction, and personal care. It manufactures and supplies its packaging solutions to the US, Canada, Mexico, Belgium, France, Spain, the UK, Italy, Germany, Australia, Brazil, Argentina, Colombia, Malaysia, India, China, and the Netherlands. The company operates more than 300 facilities around the globe and has about 47,000 employees.

Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=890

Gerresheimer AG is one of the leading companies specializing in medicine packaging, drug delivery devices, and comprehensive solutions for the pharmaceutical industry. The company is primarily dedicated to the production and supply of glass and plastic packaging solutions on a global scale for the pharmaceutical and healthcare sectors. It functions through three key business segments: plastics & devices, primary packaging glass, and advanced technologies. Gerresheimer AG conducts its pharmaceutical packaging operations through the primary packaging glass and plastics & devices segments. With a presence in 16 countries across three continents—Europe, the Americas, and Asia—the company operates 36 manufacturing plants. These locations include Poland, Mexico, Switzerland, Singapore, India, the Czech Republic, Brazil, Belgium, China, France, Denmark, Spain, North Macedonia, and the US. Employing more than 10,000 individuals, the company has a workforce of 4,504 in the plastics & devices segment and 5,333 in the primary packaging glass segment.

Amcor PLC is a leading packaging company for food, beverage, pharmaceutical, medical, home & personal care, and other products. It is primarily involved in the manufacturing and marketing of flexible packaging, rigid containers, and specialty cartons and closures by using raw materials such as polymers, aluminum foils, and fibers. The company operates through two business segments, namely, Amcor flexibles and Amcor Rigid Plastics. Amcor flexibles business produces flexible packaging for food, beverage, pharmaceutical, medical, home, and personal care, and other products, whereas Amcor’s rigid business develops and produces rigid containers and closures for food, beverage, spirits, home and personal care, and healthcare products. Amcor has a wide range of healthcare packaging for oral, dermal, medical devices, hospital packaging, ophthalmic & vision care, pulmonary, intravenous fluid, and injectables. It performs its operations through subsidiaries in the EMEA (Europe, Middle East, and Africa), the Americas, and Asia Pacific. The company operates through 220 production sites in more than 40 countries. It has 78 sales, corporate, other offices, and research sites with more than 44,000 employees. Amcor flexibles operate through 175 plants in 43 countries with more than 40,000 employees and Amcor rigid operates 50 plants in 11 countries with more than 6,000 employees.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/pharmaceutical-packaging-market-890.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pharmaceutical Packaging Market – Size, Segmental analysis, Regional Overview, Company Market share, Forecast, 2025 – 2028

New World Forensics Revolutionizes Digital Investigations with Cutting-Edge AI Technology

Miami, FL – March 12, 2025 – New World Forensics, a leader in digital forensic consulting, is transforming the industry with its advanced AI-powered forensic software. As digital evidence becomes increasingly complex and voluminous, the firm is harnessing artificial intelligence to deliver faster, more accurate investigative results.

AI-Powered Innovation in Digital Forensics

In an era where digital data is central to investigations, traditional forensic methods often struggle to keep pace. New World Forensics addresses this challenge by integrating state-of-the-art AI technology into its workflow. AI streamlines the analysis of massive datasets, enabling investigators to:

  • Rapidly Process Data: AI algorithms sift through terabytes of information in minutes, identifying relevant files and evidence that might take hours or days with manual methods.
  • Detect Patterns and Anomalies: From uncovering subtle signs of cybercrime to identifying manipulated media like deepfakes, AI enhances the ability to spot critical clues.
  • Correlate Evidence: By linking information across multiple sources, AI provides a comprehensive view of case data, improving the accuracy of findings.

These capabilities accelerate investigations while ensuring precision, making AI an indispensable tool in modern digital forensics.

Leadership Driving Industry Change

Leading this technological revolution is CEO Juan Ruiz, a veteran with over 20 years in law enforcement and 17 years in forensic consulting. Under his guidance, New World Forensics has become a pioneer in adopting and applying AI to real-world cases. Ruiz’s expertise ensures that the firm not only leverages cutting-edge tools but also tailors them to meet the unique demands of each investigation.

“AI is not just a tool; it’s a game-changer in digital forensics,” said Ruiz. “It allows us to process and analyze data at unprecedented speeds, uncovering critical evidence that might otherwise be missed. Our mission is to provide clients with the most efficient and reliable forensic services available.”

Comprehensive Forensic Solutions

New World Forensics offers a wide range of services, including computer forensics, eDiscovery, and cell phone forensics. By incorporating AI, the firm delivers deeper insights and faster results, supporting clients in fields ranging from law enforcement to corporate litigation. This blend of expertise and innovation positions New World Forensics as a trusted partner in the pursuit of justice.

About New World Forensics

New World Forensics is a premier digital forensic consulting firm based in Miami, FL. With a team of seasoned professionals and advanced technology, the firm provides comprehensive solutions across multiple forensic disciplines, setting the standard for excellence in the industry.

For more information, please contact: Media Relations, Phone: 888-322-4038, Email: media@nwflabs.com, Visit us at www.nwflabs.com

Media Contact
Company Name: New World Forensics
Email: Send Email
Phone: 888-322-4038
Country: United States
Website: www.nwflabs.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: New World Forensics Revolutionizes Digital Investigations with Cutting-Edge AI Technology

Chile Data Center Market Investment to Reach $1.24 Bn by 2030 – Arizton

“Chile Data Center Market Research Report by Arizton”
Get Insights on 37 Existing Data Centers and 09 Upcoming Facilities across Chile 

 

According to Arizton’s latest research report, the Chile data center market is growing at a CAGR of 8.27% during 2024-2030.

    

To Know More, Click: https://www.arizton.com/market-reports/chile-data-center-market

 

Report Summary     

Market Size – Investment (2030): $1.24 Billion     

Market Size – Area (2030): 230 Thousand Sq. ft.   

Market Size – Power Capacity (2030): 54 MW    

CAGR – Investment (2024-2030): 8.27%      

Colocation Market Size (2030): $375 Million 

Historic Year: 2021-2023     

Base Year: 2024     

Forecast Year: 2025-2030     

 

Chile Data Center Market Overview

Chile is home to around 37 operational colocation data centers, and the market is expected to grow significantly, positioning the country as a key emerging market for data center development in Latin America. Major operators such as Equinix, Ascenty, ODATA, Scala Data Centers, and Cirion Technologies dominate the market, with several global providers entering through strategic partnerships or acquisitions. For instance, Equinix entered the market in 2022 by acquiring data center facilities from Entel, while Actis acquired Nabiax’s data centers to launch its platform, NextStream. As of 2024, retail colocation holds a dominant 79% market share, with wholesale colocation at 21%. However, by 2030, wholesale colocation is expected to grow to around 40%, driven by increasing demand from cloud operators. Ascenty, one of the leading operators, currently manages two data centers in Santiago, generating over $14.6 million in annualized rent and maintaining a 90.1% occupancy rate. Retail colocation revenues primarily come from telecommunications, media, healthcare, and energy sectors, while wholesale colocation is mainly driven by cloud, IT, and BFSI sectors.

 

Development Plans in Chile Data Center Market

As of 2024, Santiago remains the primary hub for data center development in Chile, driven by rising demand for cloud, colocation, and digital services. Key operators such as Ascenty, Equinix, SONDA, and GTD have significantly expanded their presence in the city.

  • Equinix has developed four facilities, adding approximately 81,117 square feet of white floor space in Santiago.
  • AWS has received approval for a second data center in Huechuraba, set to have a combined area of 198,100 square feet, with the first phase expected by February 2026.
  • Cirion Technologies plans a new data center, SAN2, in the Quilicura industrial district, expected to be operational by early 2025.
  • ClaroVTR expanded its Colina data center by adding a 32,300 square feet building, bringing the total space to 53,820 square feet.
  • Ascenty operates two data centers in Santiago, with a total rentable area of 119,000 square feet by December 2024, and additional development plans for 118,000 square feet, with 71,000 square feet reserved for future expansion.

 

Chile’s Advancements in Inland and Submarine Connectivity

Chile has significantly enhanced its inland and submarine connectivity, positioning itself as a key data transit hub in South America. The country currently operates 8 submarine cables, with one more expected by 2027, improving global data traffic and regional connectivity. Investments in fiber optic networks and cables like the Humboldt Cable are helping meet the rising demand for broadband and cloud services.

Chile is also conducting a $2.2 million feasibility study for a subsea cable to connect its southernmost province with Antarctica, promoting scientific collaboration and faster data transmission by January 2025. In 2024, Hurricane Electric launched its first Point of Presence (PoP) in Santiago at Ascenty SCL2, enhancing access to high-speed IP transit and global connectivity. The Humboldt submarine cable, launching in January 2024, will directly link Chile with the Asia-Pacific region, boosting digital connectivity and supporting economic growth.

Santiago remains a major hub for data centers, but other regions like Valparaiso and Concepcion are also gaining attention due to their proximity to undersea cable systems. Overall, Chile’s improved connectivity infrastructure strengthens its role as a regional digital hub, fostering economic growth and innovation through faster data exchange and enhanced global integration.

 

Why Should You Buy this Research?

This research provides a comprehensive analysis of the Chile data center market, including:

  • Market size, investment details, power capacity, and revenue across the colocation, hyperscale, and enterprise sectors.
  • Data center investments in square feet and power capacity (MW) across six cities.
  • Existing and upcoming data centers: 37 existing and 9 upcoming facilities.
  • Colocation market trends, including revenue forecasts (2021-2030), pricing, and a breakdown of wholesale vs. retail colocation.
  • Detailed analysis of IT, power, cooling, and construction investments, with forecasts.
  • Insights on trends, growth opportunities, restraints, and market projections.
  • Overview of key IT infrastructure providers, contractors, and investors in Chile.
  • A transparent research methodology focused on demand and supply dynamics.

 

Buy this Research @ https://www.arizton.com/market-reports/chile-data-center-market

 

The Report Includes the Investment in the Following Areas:

 

IT Infrastructure

  • Server Infrastructure
  • Storage Infrastructure
  • Network Infrastructure

 

Electrical Infrastructure

  • UPS Systems
  • Generators
  • Transfer Switches & Switchgears
  • PDUs
  • Other Electrical Infrastructure

 

Mechanical Infrastructure

  • Cooling Systems
  • Racks
  • Other Mechanical Infrastructure

 

Cooling Systems

  • CRAC and CRAH Units
  • Chillers Units
  • Cooling Towers, Condensers and Dry Coolers
  • Other Cooling Units

 

General Construction

  • Core & Shell Development
  • Installation & Commissioning Services
  • Engineering & Building Design
  • Fire Detection & Suppression
  • Physical Security
  • Data Center Infrastructure Management (DCIM)

 

Tier Standard

  • Tier I & Tier II
  • Tier III
  • Tier IV

 

Vendor Landscape

 

IT Infrastructure Providers

  • Cisco
  • Dell Technologies
  • Hewlett Packard Enterprise
  • Huawei Technologies
  • IBM
  • Lenovo

 

Data Center Construction Contractors & Sub-Contractors

  • Aceco TI
  • AECOM
  • Constructora Sudamericana
  • Fluor Corporation
  • Hyphen
  • PQC
  • Turner & Townsend

 

Support Infrastructure Providers

  • ABB
  • ASSA ABLOY
  • Axis Communications
  • Bruno
  • Caterpillar
  • Cummins
  • Honeywell International
  • Johnson Controls
  • Legrand
  • Mitsubishi Electric
  • Munters
  • Piller Power Systems
  • Panduit
  • Rittal
  • Schneider Electric
  • Siemens
  • STULZ
  • Vertiv

 

Data Center Investors

  • Actis (NextStream)
  • Ascenty
  • Cirion Technologies
  • ClaroVTR
  • EdgeConneX
  • Equinix
  • Google
  • GTD
  • IPXON Networks
  • ODATA (Aligned Data Centers)
  • Scala Data Centers
  • SONDA

 

New Entrants

  • Amazon Web Services
  • Microsoft

  

Key Questions Answered in the Report:     

How big is the Chile data center market?

How much MW of power capacity will be added the Chile during 2025-2030?

What is the growth rate of the Chile data center market?

What factors are driving the Chile data center market?

       

Check Out Some of the Top Selling Reports of Your Interest:     

Brazil Data Center Market – Investment Analysis & Growth Opportunities 2025-2030

https://www.arizton.com/market-reports/brazil-data-center-market-investment-analysis-report-2025

Mexico Data Center Market – Investment Analysis & Growth Opportunities 2025-2030

https://www.arizton.com/market-reports/mexico-data-center-market-investment-analysis

 

Why Arizton?     

100% Customer Satisfaction     

24×7 availability – we are always there when you need us     

200+ Fortune 500 Companies trust Arizton’s report     

80% of our reports are exclusive and first in the industry     

100% more data and analysis      

1500+ reports published till date     

     

Post-Purchase Benefit     

  • 1hr of free analyst discussion     
  • 10% off on customization     

     

About Us:     

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.  

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.  

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.  

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1 3122332770
Country: United States
Website: https://www.arizton.com/market-reports/chile-data-center-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chile Data Center Market Investment to Reach $1.24 Bn by 2030 – Arizton

Triple Negative Breast Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Triple Negative Breast Cancer Pipeline Insight” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Triple Negative Breast Cancer pipeline landscape. It covers the Triple Negative Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Triple Negative Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Triple Negative Breast Cancer Treatment Landscape. Click here to read more @ Triple Negative Breast Cancer Pipeline Outlook

Key Takeaways from the Triple Negative Breast Cancer Pipeline Report

  • In March 2025: Novartis Pharmaceuticals conducted a study was to determine whether treatment with alpelisib in combination with nab-paclitaxel is safe and effective in subjects with advanced triple negative breast cancer (aTNBC) who carry either a PIK3CA mutation (Study Part A) or have PTEN loss (Study Part B1) or PTEN loss without PIK3CA mutation (Study Part B2).
  • In March 2025:- Providence Health & Services conducted a study is to establish the safety and tolerability of pembrolizumab when administered in combination with either of two chemotherapy regimens (weekly paclitaxel or capecitabine) in unresectable/metastatic triple negative breast cancer (MTNBC) patients.
  • In March 2025:- Rhizen Pharmaceuticals SA announced a Phase II, open-label, single-arm, study, designed to evaluate the efficacy and safety of tenalisib in patients with metastatic TNBC, who have received at least one but not more than 3 prior therapies in a metastatic setting.
  • DelveInsight’s Triple Negative Breast Cancer Pipeline analysis depicts a robust space with 75+ active players working to develop 80+ pipeline treatment therapies.
  • The leading Triple Negative Breast Cancer Companies such as Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others.
  • Promising Triple Negative Breast Cancer Pipeline Therapies such as Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Taxotere® (100 mg/m2), B013+Nab-Paclitaxel, ZEN003694, Talazoparib, Pembrolizumab, Sacituzumab Govitecan-hziy, Datopotamab Deruxtecan (Dato-DXd), and others.

Stay ahead with the most recent pipeline outlook for Triple Negative Breast Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Triple Negative Breast Cancer Treatment Drugs

Triple Negative Breast Cancer Emerging Drugs Profile

  • Camrelizumab: Jiangsu HengRui Medicine

Camrelizumab (Airuika) is a humanized monoclonal antibody acts as immunomodulatory agent. It is formulated as solution for intravenous route. Camrelizumab is indicated as third-line treatment for recurrent or refractory classical hodgkin’s lymphoma, advanced hepatocellular carcinoma patients with oxaliplatin system chemotherapy, combined with pemetrexed and carboplatin for epidermal growth factor receptor (EGFR) gene mutation negative and anaplastic lymphoma kinase (ALK) negative, non-resectable locally advanced or metastatic first-line treatment of non-squamous non-small cell lung cancer (NSCLC), locally advanced or metastatic esophageal squamous cell carcinoma patients who have previously received first-line chemotherapy and whose disease has progressed or become intolerable and for the treatment of patients with advanced nasopharyngeal carcinoma who had disease progression after previous second-line and above chemotherapy or intolerable treatment. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Triple Negative Breast Cancer.

  • SKB264: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

SKB264 is an innovative TROP2-directed ADC which was developed by OptiDC, a well-known international ADC R&D platform of Kelun-Biotech, using a proprietary payload-linker strategy (Kthiol design strategy) that achieves an optimized balance of ADC safety and efficacy by combining novel irreversible antibody conjugation chemistry, pH-sensitive payload release mechanisms, and site-specific moderately potent toxin molecules with a DAR of 7.4 (novel topoisomerase I inhibitors). SKB264 has received Breakthrough Therapy Designations (BTDs) from the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) for the treatment of locally advanced or metastatic triple-negative breast cancer.

  • AK117: Akeso Biopharma

AK117, independently developed by Akeso, is a next generation of humanized lgG4 anti-CD47 antibody without hemagglutination effect. AK117 can bind to CD47 expressed on tumor cells and block the interaction between CD47 and SIRPα, in order to enhance the phagocytic activity of phagocytes on tumor cells, thereby inhibiting the growth of tumors. Currently, the drug is in Phase II stage of clinical trial evaluation for the treatment of Triple Negative Breast Cancer.

  • PLX038: ProLynx

PLX038 is a long-acting prodrug of the topoisomerase 1 (Top1) inhibitor, SN-38, which is also the active component of anti-cancer agents irinotecan and the ADC SC. Top1 inhibitors cause DNA breaks and kill tumors that are unable to repair the damage. Previously, Curie researchers showed that about one-third of TNBC patients have defects in DNA damage repair, and should respond to an effective SN-38-based therapy (Coussy et al., 2020). In PLX038, SN-38 is covalently bound to a circulating nanoparticle and is slowly released to provide free SN-38 with a long half-life, low Cmax, and high exposure – important facets for optimal safety and efficacy. Importantly, in preclinical studies PLX038 was shown to accumulate and be retained in solid tumors, where it slowly releases its SN-38. Currently, the drug is in Phase II stage of clinical trial evaluation for the treatment of Triple Negative Breast Cancer.

  • PMD-026: Phoenix Molecular Designs

PhoenixMD’s lead candidate, PMD-026, is the first RSK inhibitor being developed for the treatment of TNBC. It is a pill that is convenient for patients as opposed to intravenous delivery, the mode most commonly used to deliver chemotherapy. PMD-026 was designed for TNBC because RSK2 was specifically identified as the key kinase that drives the growth of this breast cancer subtype5, 6. PMD-026 is well-tolerated in breast cancer patients and can stop tumor growth for up to 5 months based on Phase 1 data. PFS in women with TNBC is three times longer for patients that express high levels of RSK2 activation as compared to those with low RSK2 activation. Preclinical data shows PMD-026 has the potential to be a platform technology for chemotherapy, hormone therapy and/or immunotherapy sensitization for a wide range of refractory cancers in the future. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Triple Negative Breast Cancer.

The Triple Negative Breast Cancer Pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Triple Negative Breast Cancer with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Triple Negative Breast Cancer Treatment.
  • Triple Negative Breast Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Triple Negative Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Triple Negative Breast Cancer market

Explore groundbreaking therapies and clinical trials in the Triple Negative Breast Cancer Pipeline. Access DelveInsight’s detailed report now! @ New Triple Negative Breast Cancer Drugs

Triple Negative Breast Cancer Companies

Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others.

Triple Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Parenteral
  • intravenous
  • Subcutaneous
  • Topical

Triple Negative Breast Cancer Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

Unveil the future of Triple Negative Breast Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Triple Negative Breast Cancer Market Drivers and Barriers

Scope of the Triple Negative Breast Cancer Pipeline Report

  • Coverage- Global
  • Triple Negative Breast Cancer Companies- Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others.
  • Triple Negative Breast Cancer Pipeline Therapies- Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Taxotere® (100 mg/m2), B013+Nab-Paclitaxel, ZEN003694, Talazoparib, Pembrolizumab, Sacituzumab Govitecan-hziy, Datopotamab Deruxtecan (Dato-DXd), and others.
  • Triple Negative Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Triple Negative Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Triple Negative Breast Cancer Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Triple Negative Breast Cancer Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Triple Negative Breast Cancer Executive Summary
  3. Triple Negative Breast Cancer: Overview
  4. Triple Negative Breast Cancer Pipeline Therapeutics
  5. Triple Negative Breast Cancer Therapeutic Assessment
  6. Triple Negative Breast Cancer – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Camrelizumab: Jiangsu HengRui Medicine
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. AK117: Akeso Biopharma
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. PMD-026: Phoenix Molecular Designs
  15. Drug profiles in the detailed report…..
  16. Inactive Products
  17. Triple Negative Breast Cancer Companies
  18. Triple Negative Breast Cancer Products
  19. Triple Negative Breast Cancer Unmet Needs
  20. Triple Negative Breast Cancer Market Drivers and Barriers
  21. Triple Negative Breast Cancer Future Perspectives and Conclusion
  22. Triple Negative Breast Cancer Analyst Views
  23. Triple Negative Breast Cancer Key Companies
  24. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/triple-negative-breast-cancer-tnbc-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Triple Negative Breast Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Floor Adhesive Market Report 2025: Highlighting Growth Opportunities, Leading Players, and Market Forecasts through 2028

“Browse 160 market data Tables and 60 Figures spread through 260 Pages and in-depth TOC on “Floor Adhesive Market””
The Floor Adhesive Market is driven by rising construction activities, demand for durable flooring solutions, and eco-friendly adhesive innovations. Growth is fueled by increasing residential and commercial projects, with Asia-Pacific leading the market. Advancements in water-based adhesives further shape industry trends.

The global floor adhesives market size is projected to grow from USD 9.7 billion in 2023 to USD 12.8 billion by 2028, at a CAGR of 5.8%. The market offers a range of floor adhesives tailored to specific flooring materials. The reports 2025 research report offers an analytical view of the industry by studying different factors like floor adhesives market growth, consumption volume, Market Size, Revenue, Market Share, Market Trends, and floor adhesives industry cost structures during the forecast period from 2025 to 2028.

The floor adhesives market is divided into five key regions: North America, Europe, Asia Pacific, the Middle East & Africa, and South America. In terms of demand, Asia Pacific is expected to be the market leader over the forecast period. The floor adhesives market is intrinsically influenced by two pivotal factors: the surge in construction activities fueled by urbanization and the compelling shift towards sustainability and environmentally-friendly construction practices. As the industry responds to these driving forces, strategic alignment and innovation become imperative for capitalizing on the opportunities presented by these factors, ultimately steering the course of the floor adhesives market towards a trajectory of sustainable growth and strategic relevance.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37475603

The tile & stone segment is expected to account for one of the largest shares in 2023.

The tile and stone application segment have emerged as a pivotal catalyst, driving remarkable growth within the floor adhesives market. This surge is underpinned by a strategic interplay of factors that accentuate the significance of tile and stone installations in contemporary construction and design practices. This segment’s extraordinary expansion is a testament to the evolving preferences of consumers, the intrinsic attributes of floor adhesives, and the synergy between aesthetics, functionality, and durability.

One of the key drivers behind the substantial growth in the tile and stone application segment is the prevailing shift in consumer preferences towards these materials. Tiles and stones have garnered significant popularity due to their innate elegance, versatility, and timelessness. As modern design trends veer towards sleek aesthetics and minimalist sensibilities, tiles and stones are preferred choices for creating visually striking and sophisticated spaces. The precision and finesse required in installing these materials necessitate high-performance adhesives that can seamlessly bond these surfaces to subfloors, thereby anchoring the growth trajectory of the tile and stone application segment.

The residential segment is expected to account for the largest share in 2023.

The residential sector is unequivocally emerging as a powerhouse, propelling remarkable growth within the floor adhesives market. This robust upward trajectory finds its roots in a convergence of strategic factors, emblematic of the sector’s pivotal role in shaping the dynamics of the industry. This surge in growth within the residential segment is not a mere coincidence; rather, it is a manifestation of evolving consumer preferences, the relentless surge in housing demand, and the intrinsic alignment between contemporary living standards and the attributes of floor adhesives.

Get a Sample Copy of This Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=37475603

Central to this extraordinary growth is the ongoing evolution of consumer preferences, marked by an unyielding pursuit of elevated living standards and personalized interior spaces. In an era characterized by heightened aesthetic consciousness, homeowners and property developers are seeking flooring solutions that harmoniously blend durability, versatility, and visual allure. It is here that floor adhesives come to the fore, celebrated for their adeptness in enabling secure and long-lasting flooring installations. As residential spaces morph into havens of style and functionality, floor adhesives stand as indispensable allies in realizing these aspirations.

Asia Pacific is expected to account for one of the largest share in 2023.

Asia Pacific’s status as the largest consumer of floor adhesives is a testament to its pivotal role in the global economic landscape. The region’s dynamism, underscored by rapid urbanization, cultural diversity, and sustainability imperatives, collectively forges a conducive environment for robust adhesive demand. Industry stakeholders and market participants are poised to capitalize on this lucrative market, capitalizing on the region’s growth trajectory, and strategically aligning their offerings to address the evolving needs of the Asia Pacific floor adhesives market.

Floor Adhesive Market Companies

There are various small, medium, and large players operating in the market. Some of the major market players include Henkel AG (Germany), H.B. Fuller (US), Sika AG (Switzerland), Arkema (Bostik SA) (France), 3M (US), Dow Inc (US), Wacker Chemie AG (Germany), and Pidilite Industries Limited (India). They have adopted various developmental strategies such as investment & expansions, new product launches, mergers & acquisitions, and joint ventures to increase their share in the market.

Arkema (Bostik): Arkema is a global specialized chemical and innovative material producer with four business segments: advanced materials, coating solutions, adhesives, and intermediates. In February 2015, the firm bought Bostik SA (the world’s third-largest industrial adhesives maker) to boost its position in the specialty chemicals sector. Its adhesives are mostly utilized in the building business (both inside and outside). Bostik, the smart adhesives expert, is expanding its technological leadership in the industrial, personal care, construction, and consumer products industries three years after joining Arkema’s high-performance materials business. The corporation has around 55 countries and 144 manufacturing facilities.

Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=37475603

Wacker Chemie AG: Wacker Chemie AG is a chemical product manufacturer and distributor. Silicones, Polymers, Biosolutions, and Polysilicon are its business segments. Silicones and silicone rubber are used in consumer items, chemicals, energy and electronics applications, and building materials. Dispersions and dispersible polymer powders are produced by the Polymers section. Proteins, cyclodextrins, cysteine, and acetate solid resins are manufactured by the Biosolutions sector. For the semiconductor and electronics sectors, the Polysilicon section includes hyperpure polysilicon, chlorosilanes, and pyrogenic silicas. Other activities are included in the other parts.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/floor-adhesive-market-37475603.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Floor Adhesive Market Report 2025: Highlighting Growth Opportunities, Leading Players, and Market Forecasts through 2028